Background: HIV continues to be a major global public health concern. There are more than 38 million infected lives so far. Of the 38 million infected, 70% are in Sub-Saharan Africa. While ART is highly effective, it is not 100% effective. Primary prevention is therefore critical. Under 35% of HIV-infected individuals are aware of their status, the use of oral fluid testing is becoming an attractive approach due to its ease of use.

Objective: To analyze the performance of OraQuick ADVANCE HIV-1/2 Rapid Plasma Test and comparison of the OraQuick Rapid HIV-1 Test

Methods: We compared the oral fluid rapid plasma reagent test (OraQuick ADVANCE HIV-1/2 Rapid Plasma Test) and the oral fluid rapid test (OraQuick Rapid HIV-1 Test) with standard laboratory tests to determine the oral fluids of HIV-1/2.

Results: The OraQuick ADVANCE HIV-1/2 Rapid Plasma Test was more sensitive than the OraQuick Rapid HIV-1 Test. The OraQuick ADVANCE HIV-1/2 Rapid Plasma Test was more specific than the OraQuick Rapid HIV-1 Test.

Conclusions: The OraQuick ADVANCE HIV-1/2 Rapid Plasma Test is a promising tool for the early detection of HIV-1/2 infection.

References:

Disclaimer: The findings and views presented in this presentation are those of the author and do not necessarily represent those of the US Centers for Disease Control and Prevention.

Acknowledgements: This work was supported by the National Institutes of Health (AI134713, AI119878, and AI131107).